Rebecca Taub
CIK 1423898 · Pres., R&D, and CMO · last filed 2026-03-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$532.57M
Companies
2
Total Filings
29
Lifetime Open-Market Net
-$47.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 1,107,753 | $480.77 | $532.57M | -$47.04M | 27 | 2026-03-06 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | SVP, Research & Development | 32,500 | — | — | $9.8K | 2 | 2008-12-19 |
Recent Filings · Page 2 of 3
29 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-27 | MDGL | Sell (S) | −648 | -$217.2K | EDGAR |
| 2025-01-17 | MDGL | Sell (S) | −1,689 | -$461.8K | EDGAR |
| 2024-04-10 | MDGL | Mixed | — | -$633.0K | EDGAR |
| 2024-04-05 | MDGL | Mixed | — | -$17.32M | EDGAR |
| 2024-01-25 | MDGL | Grant (A) | +5,786 | $0 | EDGAR |
| 2024-01-18 | MDGL | Tax (F) | −1,546 | -$377.1K | EDGAR |
| 2023-01-18 | MDGL | Grant (A) | +20,001 | $0 | EDGAR |
| 2022-02-24 | MDGL | Grant (A) | — | $0 | EDGAR |
| 2021-02-23 | MDGL | Grant (A) | — | $0 | EDGAR |
| 2020-03-05 | MDGL | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.